Glycoproteomics-Based Liquid Biopsy: Translational Outlook for Colorectal Cancer Clinical Management in Southeast Asia

References

• Xi Y , XuP. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol.14(10), 101174 (2021).
   PubMed Web of Science ®Google Scholar
• Sung H , FerlayJ, SiegelRLet al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Hossain MS , KaruniawatiH, JairounAAet al. Colorectal cancer: a review of carcinogenesis, global. Cancer14(1732), 1–25 (2022).
   Google Scholar
• UNESCAP . South-East Asia: demographic indicators. www.population-trends-asiapacific.org/data/sea
   Google Scholar
• Ouakrim DA , PizotC, BoniolMet al. Trends in colorectal cancer mortality in Europe: retrospective analysis of the WHO mortality database. BMJ351, h4970 (2015).
   PubMed Web of Science ®Google Scholar
• Rustgi AK . The genetics of hereditary colon cancer. Genes Dev.21(20), 2525–2538 (2007).
   PubMed Web of Science ®Google Scholar
• Wang H , SeowA, LeeHP. Trends in cancer incidence among Singapore Malays: a low-risk population. Ann. Med. Singapore33(1), 57–62 (2004).
   PubMed Web of Science ®Google Scholar
• Hassan MRA , IsmailI, SuanMAMet al. Incidence and mortality rates of colorectal cancer in Malaysia. Epidemiol. Health38, e2016007 (2016).
   PubMedGoogle Scholar
• UNESCAP . Economic and social survey of Asia and the Pacific 2017: governance and fiscal management (2017). www.unescap.org/publications/economic-and-social-survey-asia-and-pacific-2017
   Google Scholar
• Bailey CE , HuC-Y, YouYNet al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg.150(1), 17–22 (2015).
   PubMed Web of Science ®Google Scholar
• Mauri G , VitielloPP, SogariAet al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. Br. J. Cancer127(3), 394–407 (2022).
   PubMed Web of Science ®Google Scholar
• Ding Y , LiW, WangK, XuC, HaoM, DingL. Perspectives of the application of liquid biopsy in colorectal cancer. Biomed Res. Int.2020, 6843180 (2020).
   PubMed Web of Science ®Google Scholar
• Marcuello M , VymetalkovaV, NevesRPLet al. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol. Aspects Med.69, 107–122 (2019).
   PubMed Web of Science ®Google Scholar
• Normanno N , CervantesA, CiardielloF, DeLuca A, PintoC. The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios. Cancer Treat. Rev.70, 1–8 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang W , YangZ, GaoX, WuQ. Advances in the discovery of novel biomarkers for cancer: spotlight on protein N-glycosylation. Biomark. Med.14(11), 1031–1045 (2020).
   PubMed Web of Science ®Google Scholar
• Fearon ER , VogelsteinB. A genetic model for colorectal tumorigenesis. Cell61(5), 759–767 (1990).
   PubMed Web of Science ®Google Scholar
• Smith G , CareyFA, BeattieJet al. Mutations in APC, Kirsten-ras, and p53 – alternative genetic pathways to colorectal cancer. Proc. Natl Acad. Sci. USA99(14), 9433–9438 (2002).
   PubMed Web of Science ®Google Scholar
• Rex DK , SullivanAW, PerkinsAJ, VemulapalliKC. Colorectal polyp prevalence and aspirational detection targets determined using high definition colonoscopy and a high level detector in 2017. Dig. Liver Dis.52(1), 72–78 (2020).
   PubMedGoogle Scholar
• Corley DA , JensenCD, MarksARet al. Adenoma detection rate and risk of colorectal cancer and death. N. Engl. J. Med.370(14), 1298–1306 (2014).
   PubMed Web of Science ®Google Scholar
• Binefa G , Rodríguez-MorantaF, TeuleA, Medina-HayasM. Colorectal cancer: from prevention to personalized medicine. World J. Gastroenterol.20(22), 6786 (2014).
   PubMed Web of Science ®Google Scholar
• Schliemann D , ParamasivamD, DahluiMet al. Change in public awareness of colorectal cancer symptoms following the Be Cancer Alert Campaign in the multi-ethnic population of Malaysia. BMC Cancer20(1), 1–12 (2020).
   Web of Science ®Google Scholar
• Hassan MRA , KhazimWKW, MustaphaNRN, OthmanZ. National cancer patient registry-colorectal cancer in Malaysia. Ann. Oncol.24, iv97 (2013).
   Google Scholar
• Siegel RL , MillerKD, GodingSauer Aet al. Colorectal cancer statistics, 2020. CA Cancer J. Clin.70(3), 145–164 (2020).
   PubMed Web of Science ®Google Scholar
• Andrei P , BattuelloP, GrassoG, RoveraE, TesioN, BardelliA. Integrated approaches for precision oncology in colorectal cancer: the more you know, the better. Semin. Cancer Biol.84, 199–213 (2021).
   PubMed Web of Science ®Google Scholar
• American Cancer Society Cancer facts and statistics (2015). www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2015.html
   Google Scholar
• Levin B , LiebermanDA, McFarlandBet al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology134(5), 1570–1595 (2008).
   PubMed Web of Science ®Google Scholar
• Simon K . Colorectal cancer development and advances in screening. Clin. Interv. Aging11, 967 (2016).
   PubMed Web of Science ®Google Scholar
• Mandel JS , BondJH, ChurchTRet al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N. Engl. J. Med.328(19), 1365–1371 (1993).
   PubMed Web of Science ®Google Scholar
• Bailey JR , AggarwalA, ImperialeTF. Colorectal cancer screening: stool DNA and other noninvasive modalities. Gut Liver10(2), 204 (2016).
   PubMed Web of Science ®Google Scholar
• Schreuders EH , GrobbeeEJ, SpaanderMCW, KuipersEJ. Advances in fecal tests for colorectal cancer screening. Curr. Treat. Options Gastroenterol.14(1), 152–162 (2016).
   PubMedGoogle Scholar
• Dhaliwal A , VlachostergiosPJ, OikonomouKG, MoshenyatY. Fecal DNA testing for colorectal cancer screening: molecular targets and perspectives. World J. Gastrointest. Oncol.7(10), 178 (2015).
   PubMed Web of Science ®Google Scholar
• Ebell MH . Accuracy of fecal DNA and fecal immunochemical test for colorectal cancer detection. Am. Fam. Physician90(5), 326 (2014).
   Web of Science ®Google Scholar
• Vacante M , CiuniR, BasileF, BiondiA. The liquid biopsy in the management of colorectal cancer: an overview. Biomedicines8(9), 308 (2020).
   PubMed Web of Science ®Google Scholar
• Nakayama G , TanakaC, KoderaY. Current options for the diagnosis, staging and therapeutic management of colorectal cancer. Gastrointest. Tumors1(1), 25–32 (2014).
   Google Scholar
• Zauber AG , WinawerSJ, O’BrienMJet al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N. Engl. J. Med.366, 687–696 (2012).
   PubMed Web of Science ®Google Scholar
• De Wijkerslooth TR , BossuytPM, DekkerE. Strategies in screening for colon carcinoma. Neth. J. Med.69(3), 112–119 (2011).
   PubMed Web of Science ®Google Scholar
• Baxter N , RabeneckL. New findings about the risks and limitations of colonoscopy used in the early detection of colorectal cancer. Healthc. Q.12(2), 24–25 (2009).
   PubMedGoogle Scholar
• Cuyle P-J , PrenenH. Current and future biomarkers in the treatment of colorectal cancer. Acta Clin. Belg.72(2), 103–115 (2017).
   PubMed Web of Science ®Google Scholar
• Tournigand C , AndreT, BonnetainFet al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J. Clin. Oncol.30(27), 3353–3360 (2012).
   PubMed Web of Science ®Google Scholar
• Andre T , BoniC, Mounedji-BoudiafLet al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med.350(23), 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• Haller DG , TaberneroJ, MarounJet al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J. Clin. Oncol.29(11), 1465–1471 (2011).
   PubMed Web of Science ®Google Scholar
• Yothers G , O’ConnellMJ, AllegraCJet al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J. Clin. Oncol.29(28), 3768 (2011).
   PubMed Web of Science ®Google Scholar
• Ciombor KK , WuC, GoldbergRM. Recent therapeutic advances in the treatment of colorectal cancer. Annu. Rev. Med.66, 83–95 (2015).
   PubMed Web of Science ®Google Scholar
• Carethers JM . Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor. Therap. Adv. Gastroenterol.1(1), 33–42 (2008).
   PubMedGoogle Scholar
• Wolpin BM , MayerRJ. Systemic treatment of colorectal cancer. Gastroenterology.134(5), 1296–1310 (2008).
   PubMed Web of Science ®Google Scholar
• Imperiale TF , RansohoffDF, ItzkowitzSHet al. Multitarget stool DNA testing for colorectal-cancer screening. N. Engl. J. Med.370(14), 1287–1297 (2014).
   PubMed Web of Science ®Google Scholar
• Inadomi JM , VijanS, JanzNKet al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch. Intern. Med.172(7), 575–582 (2012).
   PubMedGoogle Scholar
• Lone SN , NisarS, MasoodiTet al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol. Cancer21(1), 1–22 (2022).
   PubMed Web of Science ®Google Scholar
• Oshi M , MurthyV, TakahashiHet al. Urine as a source of liquid biopsy for cancer. Cancers (Basel).13(11), 2652 (2021).
   PubMed Web of Science ®Google Scholar
• Lim M , KimC-J, SunkaraV, KimM-H, ChoY-K. Liquid biopsy in lung cancer: clinical applications of circulating biomarkers (CTCs and ctDNA). Micromachines9(3), 100 (2018).
   PubMed Web of Science ®Google Scholar
• Kudryavtseva AV , LipatovaAV, ZaretskyARet al. Important molecular genetic markers of colorectal cancer. Oncotarget7(33), 53959 (2016).
   PubMed Web of Science ®Google Scholar
• Watanabe T , KanazawaT, KazamaY, TanakaJ, TanakaT, NagawaH. Microsatellite instability in adenoma as a possible marker to identify HNPCC patients. Am. J. Gastroenterol.101(1), 204 (2006).
   PubMed Web of Science ®Google Scholar
• Ellegren H . Microsatellites: simple sequences with complex evolution. Nat. Rev. Genet.5(6), 435–445 (2004).
   PubMed Web of Science ®Google Scholar
• Yamamoto H , ImaiK. Microsatellite instability: an update. Arch. Toxicol.89(6), 899–921 (2015).
   PubMed Web of Science ®Google Scholar
• Setaffy L , LangnerC. Microsatellite instability in colorectal cancer: clinicopathological significance. Polish J. Pathol.66(3), 203–218 (2015).
   PubMed Web of Science ®Google Scholar
• Casak SJ , MarcusL, Fashoyin-AjeLet al. FDA approval summary: pembrolizumab for the first-line treatment of patients with MSI-H/dMMR advanced unresectable or metastatic colorectal carcinoma. Clin. Cancer Res.27(17), 4680–4684 (2021).
   PubMed Web of Science ®Google Scholar
• Aguiar-Ibáñez R , HardernC, van HeesFet al. Cost–effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States. J. Med. Econ.25(1), 469–480 (2022).
   PubMed Web of Science ®Google Scholar
• Lofton-Day C , ModelF, DeVosTet al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clin. Chem.54(2), 414–423 (2008).
   PubMed Web of Science ®Google Scholar
• Han M , LiewCT, ZhangHWet al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin. Cancer Res.14(2), 455–460 (2008).
   PubMed Web of Science ®Google Scholar
• Oh T , KimN, MoonYet al. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J. Mol. Diagnostics15(4), 498–507 (2013).
   PubMed Web of Science ®Google Scholar
• Thierry AR , MouliereF, ElMessaoudi Set al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med.20(4), 430–435 (2014).
   PubMed Web of Science ®Google Scholar
• Yen L-C , YehY-S, ChenC-Wet al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin. Cancer Res.15(13), 4508–4513 (2009).
   PubMed Web of Science ®Google Scholar
• Habermann JK , RoblickUJ, LukeBTet al. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology131(4), 1020–1029 (2006).
   PubMed Web of Science ®Google Scholar
• Albrethsen J , BøgeboR, GammeltoftS, OlsenJ, WintherB, RaskovH. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer5(1), 1–10 (2005).
   PubMedGoogle Scholar
• Lee H , RheeH, KangHJet al. Macrophage migration inhibitory factor may be used as an early diagnostic marker in colorectal carcinomas. Am. J. Clin. Pathol.129(5), 772–779 (2008).
   PubMed Web of Science ®Google Scholar
• Mroczko B , GroblewskaM, Wereszczynska-SiemiatkowskaU, KedraB, KonopkoM, SzmitkowskiM. The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. Clin. Chim. Acta371(1–2), 143–147 (2006).
   PubMed Web of Science ®Google Scholar
• Yu J , ZhaiX, LiXet al. Identification of MST1 as a potential early detection biomarker for colorectal cancer through a proteomic approach. Sci. Rep.7(1), 1–10 (2017).
   PubMed Web of Science ®Google Scholar
• Xie Y-H , ChenY-X, FangJ-Y. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct. Target. Ther.5(1), 1–30 (2020).
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C , PantelK. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov.6(5), 479–491 (2016).
   PubMed Web of Science ®Google Scholar
• Markou A , TzanikouE, LianidouE. The potential of liquid biopsy in the management of cancer patients. Semin. Cancer Biol.84, 69–79 (2022).
   PubMed Web of Science ®Google Scholar
• Dasari A , MorrisVK, AllegraCJet al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper. Nat. Rev. Clin. Oncol.17(12), 757–770 (2020).
   PubMed Web of Science ®Google Scholar
• Batth IS , MitraA, ManierSet al. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann. Oncol.28(3), 468–477 (2017).
   PubMed Web of Science ®Google Scholar
• Siravegna G , MarsoniS, SienaS, BardelliA. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol.14(9), 531–548 (2017).
   PubMed Web of Science ®Google Scholar
• Yu W , HurleyJ, RobertsDet al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann. Oncol.32(4), 466–477 (2021).
   PubMed Web of Science ®Google Scholar
• Ludwig JA , WeinsteinJN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer5(11), 845–856 (2005).
   PubMed Web of Science ®Google Scholar
• Gutierrez-Reyes CD , JiangP, AtashiMet al. Advances in mass spectrometry-based glycoproteomics: an update covering the period 2017–2021. Electrophoresis43(1–2), 370–387 (2022).
   PubMed Web of Science ®Google Scholar
• Peixoto A , Relvas-SantosM, AzevedoR, SantosLL, FerreiraJA. Protein glycosylation and tumor microenvironment alterations driving cancer hallmarks. Front. Oncol.9(9), 380 (2019).
   PubMedGoogle Scholar
• Hanzawa K , Tanaka-OkamotoM, MurakamiHet al. Increased levels of acidic free-N-glycans, including multi-antennary and fucosylated structures, in the urine of cancer patients. PLOS ONE17(4), e0266927 (2022).
   PubMed Web of Science ®Google Scholar
• Azevedo R , PeixotoA, GaiteiroCet al. Over forty years of bladder cancer glycobiology: where do glycans stand facing precision oncology? Oncotarget 8(53), 91734–91764 (2017).
   PubMedGoogle Scholar
• Reily C , StewartTJ, RenfrowMB, NovakJ. Glycosylation in health and disease. Nat. Rev. Nephrol.15(6), 346–366 (2019).
   PubMed Web of Science ®Google Scholar
• Bennett EP , MandelU, ClausenH, GerkenTA, FritzTA, TabakLA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology22(6), 736–756 (2012).
   PubMed Web of Science ®Google Scholar
• Schjoldager KT , NarimatsuY, JoshiHJ, ClausenH. Global view of human protein glycosylation pathways and functions. Nat. Rev. Mol. Cell Biol.21(12), 729–749 (2020).
   PubMed Web of Science ®Google Scholar
• Kailemia MJ , ParkD, LebrillaCB. Glycans and glycoproteins as specific biomarkers for cancer. Anal. Bioanal. Chem.409, 395–410 (2017).
   PubMed Web of Science ®Google Scholar
• Locker GY , HamiltonS, HarrisJet al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol.24(33), 5313–5327 (2006).
   PubMed Web of Science ®Google Scholar
• Duffy MJ . Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?Clin. Chem.47(4), 624–630 (2001).
   PubMed Web of Science ®Google Scholar
• Xie H-L , GongY-Z, KuangJ-A, GaoF, TangS-Y, GanJ-L. The prognostic value of the postoperative serum CEA levels/preoperative serum CEA levels ratio in colorectal cancer patients with high preoperative serum CEA levels. Cancer Manag. Res.11, 7499 (2019).
   PubMed Web of Science ®Google Scholar
• Ferreira JA , MagalhaesA, GomesJet al. Protein glycosylation in gastric and colorectal cancers: toward cancer detection and targeted therapeutics. Cancer Lett.387, 32–45 (2017).
   PubMed Web of Science ®Google Scholar
• Pinho SS , ReisCA. Glycosylation in cancer: mechanisms and clinical implications. Nat. Rev. Cancer15(9), 540–555 (2015).
   PubMed Web of Science ®Google Scholar
• Mereiter S , BalmanaM, CamposD, GomesJ, ReisCA. Glycosylation in the era of cancer-targeted therapy: where are we heading?Cancer Cell36(1), 6–16 (2019).
   PubMed Web of Science ®Google Scholar
• Marcos NT , BennettEP, GomesJet al. ST6GalNAc-I controls expression of sialyl-Tn antigen in gastrointestinal tissues. Front. Biosci.3(4), 1443–1455 (2011).
   Google Scholar
• Reis CA , OsorioH, SilvaL, GomesC, DavidL. Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol.63(4), 322–329 (2010).
   PubMed Web of Science ®Google Scholar
• Fernandes E , SoresJ, CottonSet al. Esophageal, gastric and colorectal cancers: looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology. Theranostics10(11), 4903–4928 (2020).
   PubMed Web of Science ®Google Scholar
• Van’t Veer LJ , DaiH, VanDe Vijver MJet al. Gene expression profiling predicts clinical outcome of breast cancer. Nature415(6871), 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• Espina V , WoodhouseEC, WulfkuhleJ, AsmussenHD, PetricoinEFIII, LiottaLA. Protein microarray detection strategies: focus on direct detection technologies. J. Immunol. Methods290(1–2), 121–133 (2004).
   PubMed Web of Science ®Google Scholar
• Kulasingam V , DiamandisEP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol.5(10), 588–599 (2008).
   PubMedGoogle Scholar
• Abrahams JL , TaherzadehG, JarvasG, GuttmanA, ZhouY, CampbellMP. Recent advances in glycoinformatic platforms for glycomics and glycoproteomics. Curr. Opin. Struct. Biol.62, 56–69 (2020).
   PubMed Web of Science ®Google Scholar
• Ruhaak LR , ZaunerG, HuhnC, BrugginkC, DeelderAM, WuhrerM. Glycan labeling strategies and their use in identification and quantification. Anal. Bioanal. Chem.397(8), 3457–3481 (2010).
   PubMed Web of Science ®Google Scholar
• Kay Li Q , GabrielsonE, ZhangH. Application of glycoproteomics for the discovery of biomarkers in lung cancer. Proteomics Clin. Appl.6(5–6), 244–256 (2012).
   PubMed Web of Science ®Google Scholar
• Engwegen JYMN , HelgasonHH, CatsAet al. Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J. Gastroenterol.12(10), 1536 (2006).
   PubMed Web of Science ®Google Scholar
• Mesri M . Advances in proteomic technologies and its contribution to the field of cancer. Adv. Med.2014, 238045 (2014).
   PubMedGoogle Scholar
• Mendes ML , DittmarG. Targeted proteomics on its way to discovery. Proteomics22(15–16), 2100330 (2022).
   Web of Science ®Google Scholar
• Riley NM , BertozziCR, PitteriSJ. A pragmatic guide to enrichment strategies for mass spectrometry-based glycoproteomics. Mol. Cell. Proteomics20, 100029 (2021).
   PubMed Web of Science ®Google Scholar
• Shen F , XiongY, ZhangLet al. Rapid sample preparation workflow for serum sample analysis with different mass spectrometry acquisition strategies. Anal. Chem.93(3), 1578–1585 (2020).
   PubMed Web of Science ®Google Scholar
• Shinozaki E , TanabeK, AkiyoshiTet al. Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker. BMC Cancer18, 406 (2018).
   PubMed Web of Science ®Google Scholar
• Qiu Y , PatwaTH, XuLet al. Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J. Proteome Res.7(4), 1693–1703 (2008).
   PubMed Web of Science ®Google Scholar
• Lindpaintner K , DesaiK, XuGet al. Identifying potential glycoproteomic biomarkers for diagnosis of colorectal cancer (CRC). J. Clin. Oncol.40(Suppl. 16), e15529 (2022).
   Web of Science ®Google Scholar
• Wei H , ChengZ, OuyangCet al. Glycoprotein screening in colorectal cancer based on differentially expressed Tn antigen. Oncol. Rep.36(3), 1313–1324 (2016).
   PubMed Web of Science ®Google Scholar
• Gong Q , ZhangX, LiangAet al. Proteomic screening of potential N-glycoprotein biomarkers for colorectal cancer by TMT labeling combined with LC–MS/MS. Clin. Chim. Acta521, 122–130 (2021).
   PubMed Web of Science ®Google Scholar
• Lindpaintner K , MitchellA, PickeringCet al. Glycoproteomics as a powerful liquid biopsy-based predictor of checkpoint inhibitor treatment benefit in metastatic malignant melanoma. J. Clin. Oncol.40(Suppl. 16), 9545 (2022).
   Google Scholar
• Mitchell A , SrinivasanA, XuGet al. Predicting breast cancer in women using liquid biopsy-derived glycoproteomic markers. J. Clin. Oncol.40(Suppl. 16), e12545 (2022).
   Web of Science ®Google Scholar
• Mitchell A , PickeringC, XuGet al. Glycoproteomics as a powerful liquid biopsy-based screening tool for non-small cell lung cancer. J. Clin. Oncol.40(Suppl. 16), e21148 (2022).
   Web of Science ®Google Scholar
• Serie D , MoserK, PickeringCet al. Liquid-biopsy-derived glycoproteomic profiling as a novel means for noninvasive diagnosis of ovarian cancer. J. Clin. Oncol.40(Suppl. 16), e17604 (2022).
   Web of Science ®Google Scholar
• Serie D , PickeringC, RiceRet al. Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy. J. Clin. Oncol.40(Suppl. 16), 11546 (2022).
   Web of Science ®Google Scholar
• Al-wajeeh AS , IsmailMN, SalhimiSMet al. Identification of glycobiomarker candidates for breast cancer using LTQ-Orbitrap fusion technique. Int. J. Pharmacol.13(5), 425–437 (2017).
   Google Scholar
• Wong Y-L , AnandR, YuenKMet al. Identification of potential glycoprotein biomarkers in oral squamous cell carcinoma using sweet strategies. Glycoconj. J.38(1), 1–11 (2021).
   PubMed Web of Science ®Google Scholar
• Chokchaichamnankit D , WatcharatanyatipK, SubhasitanontPet al. Urinary biomarkers for the diagnosis of cervical cancer by quantitative label-free mass spectrometry analysis. Oncol. Lett.17(6), 5453–5468 (2019).
   PubMed Web of Science ®Google Scholar
• Boonyapranai K , OunjaijeanS, KulprachakarnKet al. Haptoglobin polymorphisms and fucosylation change: possible influence of variation on the identified lung cancer-relevant biomarkers. Curr. Proteomics18(3), 380–389 (2020).
   Web of Science ®Google Scholar
• Chantaraamporn J , ChampattanachaiV, KhongmaneeAet al. Glycoproteomic analysis reveals aberrant expression of complement C9 and fibronectin in the plasma of patients with colorectal cancer. Proteomes8(3), 26 (2020).
   PubMed Web of Science ®Google Scholar
• Ye Z , VakhrushevSY. The role of data-independent acquisition for glycoproteomics. Mol. Cell Proteomics20, 100042 (2021).
   PubMed Web of Science ®Google Scholar
• Iqbal MJ , JavedZ, SadiaHet al. Clinical applications of artificial intelligence and machine learning in cancer diagnosis: looking into the future. Cancer Cell Int.21(1), 270 (2021).
   PubMed Web of Science ®Google Scholar
• Nabirotchkin S , PeluffoAE, RinaudoP, YuJ, HajjR, CohenD. Next-generation drug repurposing using human genetics and network biology. Curr. Opin. Pharmacol.51, 78–92 (2020).
   PubMed Web of Science ®Google Scholar
• Lindpaintner K . Glycoproteomics: a new era in biomarkers (2021). www.labnews.co.uk/article/2031446/glycoproteomics-a-new-era-in-biomarkers
   Google Scholar
• Ginghina O , HuditaA, ZamfirMet al. Liquid biopsy and artificial intelligence as tools to detect signatures of colorectal malignancies: a modern approach in patient’s stratification. Front. Oncol.12(March), 1–22 (2022).
   Google Scholar
• Dlamini Z , FranciesFZ, HullR, MarimaR. Artificial intelligence (AI) and big data in cancer and precision oncology. Comput. Struct. Biotechnol. J.18, 2300–2311 (2020).
   PubMed Web of Science ®Google Scholar
• Wang Y , HeX, NieH, ZhouJ, CaoP, OuC. Application of artificial intelligence to the diagnosis and therapy of colorectal cancer. Am. J. Cancer Res.10(11), 3575–3598 (2020).
   PubMed Web of Science ®Google Scholar
• Kasi PM , ShenL, RamachandranPet al. Serum glycoproteomic-based liquid biopsy for the detection of pancreatic ductal adenocarcinoma. J. Clin. Oncol.38(Suppl. 4), 763 (2020).
   Google Scholar
• Lindpaintner K , ChengM, PrendergastJet al. Blood-based glycoprotien signatures in advanced non-small-cell lung carcinoma (NSCLC) receiving first-line immune checkpoint blockade. J. Immunother. Cancer9(Suppl. 2), A35 (2021).
   Google Scholar
• Ramachandran P , XuG, HuangHHet al. Serum glycoprotein markers in nonalcoholic steatohepatitis and hepatocellular carcinoma. J. Proteome Res.21(4), 1083–1094 (2022).
   PubMed Web of Science ®Google Scholar
• Pickering C , ZhouB, XuGet al. Differential peripheral blood glycoprotein profiles in symptomatic and asymptomatic COVID-19. Viruses14(3), 553 (2022).
   PubMed Web of Science ®Google Scholar
• Mitsala A , TsalikidisC, PitiakoudisM, SimopoulosC, TsarouchaAK. Artificial intelligence in colorectal cancer screening, diagnosis and treatment. A new era. Curr. Oncol.28(3), 1581–1607 (2021).
   PubMed Web of Science ®Google Scholar
• Zhou H , ZhuL, SongJet al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol. Cancer21(1), 86 (2022).
   PubMed Web of Science ®Google Scholar
• Taghiakbari M , MoriY, von RentelnD. Artificial intelligence-assisted colonoscopy: a review of current state of practice and research. World J. Gastroenterol.27(47), 8103 (2021).
   PubMed Web of Science ®Google Scholar
• Wang W , YinY, ShanXet al. The value of plasma-based microRNAs as diagnostic biomarkers for ovarian cancer. Am. J. Med. Sci.358(4), 256–267 (2019).
   PubMed Web of Science ®Google Scholar
• Chen H , ZhouQ. Detecting liquid remnants of solid tumors treated with curative intent: circulating tumor DNA as a biomarker of minimal residual disease. Oncol. Rep.49(5), 1–13 (2023).
   PubMed Web of Science ®Google Scholar
• Almeida A , KolarichD. The promise of protein glycosylation for personalised medicine. Biochim. Biophys. Acta1860(8), 1583–1595 (2016).
   PubMed Web of Science ®Google Scholar
• Jain KK . Role of oncoproteomics in the personalized management of cancer. Expert Rev. Proteomics1(1), 49–55 (2004).
   PubMed Web of Science ®Google Scholar
• Gubatan J , LevitteS, PatelA, BalabanisT, WeiMT, SinhaSR. Artificial intelligence applications in inflammatory bowel disease: emerging technologies and future directions. World J. Gastroenterol.27(17), 1920 (2021).
   PubMed Web of Science ®Google Scholar
• Liu Y , ZhangC, WangQet al. Global, regional, and national burden of colorectal cancer and attributable risk factors, from 1990 to 2019: updated results from the Global Burden of Disease Study 2019. Res. Square7(7), 627–647 (2022).
   Google Scholar
• Soon S , ChiaJW, ChewMH, TanWS, YangXY, WeeHL. Gender-specific patterns of productivity loss in colorectal cancer survivors in a multi-ethnic Asian population. Value Health19(7), A807 (2016).
   Web of Science ®Google Scholar
• WHO . Cardiovascular diseases, diabetes and cancer cost nearly RM 9 billion productivity losses annually to Malaysian economy (2020). www.who.int/malaysia/news/detail/08-09-2020-cardiovascular-diseases-diabetes-and-cancer-cost-nearly-rm-9-billion-productivity-losses-annually-to-malaysian-economy
   Google Scholar
• Kong Y-C , SaktiV-V, SullivanR, Bhoo-PathyN. Cancer and COVID-19: economic impact on households in southeast Asia. Ecancermedicalscience14, 1134 (2020).
   PubMed Web of Science ®Google Scholar
• Azzani M , DahluiM, IshakWZW, RoslaniAC, SuTT. Provider costs of treating colorectal cancer in government hospital of Malaysia. Malaysian J. Med. Sci.26(1), 73 (2019).
   Google Scholar
• Bradley CJ , Lansdorp-VogelaarI, YabroffKRet al. Productivity savings from colorectal cancer prevention and control strategies. Am. J. Prev. Med.41(2), e5–e14 (2011).
   PubMed Web of Science ®Google Scholar
• Heavener T , McStayFW, JaegerVet al. Assessing adherence and cost-benefit of colorectal cancer screening for accountable providers. Presented at: Baylor University Medical Center Proceedings. Taylor & Francis.32(4), 490–497 (2019).
   Google Scholar
• van Ballegooijen M , HabbemaJDF, BoerRet al. Acomparison of the cost-effectiveness of fecal occult blood tests with different test characteristics in the context of annual screening in the Medicare population. (2015).
   Google Scholar
• UKM . Colorectal Cancer Screening | The Malaysian Cohort. https://www.ukm.my/mycohort/ms/colorectal-cancer-screening/
   Google Scholar
• Cologuard® Cost | Cologuard Patient Site. https://www.cologuard.com/affordable
   Google Scholar
• Guardant Health, Inc. Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360R CDx Test. https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant-Health-Receives-ADLT-Status-from-CMS-for-FDA-Approved-Guardant360-CDx-Test/default.aspx
   Google Scholar
• Karol D , McKinnonM, MukhtarLet al. The impact of foundation medicine testing on cancer patients: A single academic centre experience. Front. Oncol.11, 687730 (2021).
   PubMed Web of Science ®Google Scholar
• Young PE , WomeldorphCM. Colonoscopy for colorectal cancer screening. J. Cancer4(3), 217–226 (2013).
   PubMed Web of Science ®Google Scholar
• Osborne JM , WilsonC, MooreV, GregoryT, FlightI, YoungGP. Sample preference for colorectal cancer screening tests: blood or stool?Open J. Prev. Med.2(3), 326–331 (2012).
   Google Scholar
• Precedence Research . Liquid Biopsy Market Size to Hit US$ 26.2 Billion by 2030 (2021). www.globenewswire.com/en/news-release/2021/12/14/2351913/0/en/Liquid-Biopsy-Market-Size-to-Hit-US-26-2-Billion-by-2030.html
   Google Scholar
• Timothy G . ‘Singapore medical company invents non-invasive cancer screening tests; receives US$20m in funding | The Straits Times’ (2019). www.straitstimes.com/singapore/health/singapore-medical-company-invents-non-invasive-cancer-screening-tests-receives
   Google Scholar
• Mazouji O , OuhajjouA, IncittiR, MansourH. Updates on clinical use of liquid biopsy in colorectal cancer screening, diagnosis, follow-up, and treatment guidance. Front. Cell Dev. Biol.9(May), 660924 (2021).
   PubMedGoogle Scholar
• Bakker E , HendrikseNM, EhmannFet al. Biomarker qualification at the European Medicines Agency: a review of biomarker qualification procedures from 2008 to 2020. Clin. Pharmacol. Ther.112(1), 69–80 (2022).
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration . HHS. International conference on harmonisation; guidance on e16 biomarkers related to drug or biotechnology product development: context, structure, and format of qualification submissions; availability. Notice. Federal register76(155), 49773–49774 (2011).
   PubMedGoogle Scholar
• Menetski JP , HoffmannSC, CushSSet al. The Foundation for the National Institutes of Health Biomarkers Consortium: past accomplishments and new strategic direction. Clin. Pharmacol. Ther.105(4), 829–843 (2019).
   PubMed Web of Science ®Google Scholar
• See HY , MohamedMS, NorSNM, LowWY. Challenges in the ethical review of clinical and biomedical research in Malaysia: a mixed methods study. J. Empir. Res. Hum. Res. Ethics16(5), 487–500 (2021).
   PubMed Web of Science ®Google Scholar
• Glasziou P , ScottAM, ChalmersI, KolstoeSE, DaviesHT. Improving research ethics review and governance can improve human health. J. R. Soc. Med.114(12), 556–562 (2021).
   PubMed Web of Science ®Google Scholar
• Universiti Kebangsaan Malaysia . BIOBANK | UKM Medical Molecular Biology Institute (2022). www.ukm.my/umbi/?s=BIOBANK
   Google Scholar
• Zain RB , AthirajanV, GhaniWMNet al. An oral cancer biobank initiative: a platform for multidisciplinary research in a developing country. Cell Tissue Bank.14(1), 45–52 (2013).
   PubMed Web of Science ®Google Scholar
• Baláž V , JeckT, BalogM. Economics of biobanking: business or public good? Literature review, structural and thematic analysis. Soc. Sci.11(7), 288 (2022).
   Google Scholar
• Chong HY , AlloteyPA, ChaiyakunaprukN. Current landscape of personalized medicine adoption and implementation in southeast Asia. BMC Med. Genomics11(1), 1–15 (2018).
   PubMedGoogle Scholar